New "me-too" beta blocker dissed by experts

The Wall Street Journal health blog pokes fun at Bystolic, the newly approved beta blocker from Forest Laboratories and Mylan Laboratories, as the ultimate "me-too" drug. It's number 19 in the list of beta blockers now available in the U.S. The developers counter by saying that the drug has "placebo-like" side effects, making compliance easier. One Mayo Clinic expert cautions the numbers are coming from small studies, and with Glaxo's Coreg going generic, he's going with the lower cost drug.

- read the blog item

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.